ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Urokinase Lyophilized Powder Market Research Report 2026
Published Date: 2026-01-13
|
Report Code: QYRE-Auto-35C10014
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Urokinase Lyophilized Powder Market Insights Forecast to 2028
BUY CHAPTERS

Global Urokinase Lyophilized Powder Market Research Report 2026

Code: QYRE-Auto-35C10014
Report
2026-01-13
Pages:117
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
LIVZON
Syner-Med
Microbic Biosystems
Wuhan Humanwell Pharma
Tianjin Biochem Pharma

Urokinase Lyophilized Powder Market Size

The global Urokinase Lyophilized Powder market was valued at US$ 74.70 million in 2025 and is anticipated to reach US$ 112 million by 2032, at a CAGR of 5.5% from 2026 to 2032.

Urokinase Lyophilized Powder Market

Urokinase Lyophilized Powder Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Urokinase Lyophilized Powder competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Urokinase is a clot-dissolving medicine. It is a natural enzyme (a protein) that activates the body’s own fibrinolytic system by converting plasminogen into plasmin, and plasmin then breaks down fibrin, which is the “mesh” that holds a blood clot together. This is why urokinase is called a thrombolytic or “clot-buster.” The market for urokinase mainly includes injectable products (usually a sterile powder that is dissolved before use) that are given in hospitals, either through a vein or through a catheter directly to the clot area, depending on the indication and local practice. The clinical risk that shapes this market is also simple: because the drug dissolves clots, it can also weaken normal clotting at injury sites, so bleeding is the key safety concern and a major reason urokinase is used in controlled hospital settings.
A practical market definition should also include how urokinase is made, because that affects supply, regulatory burden, and cost. Urokinase products can differ by source. The U.S. Kinlytic label describes production from human neonatal kidney cells grown in tissue culture, and it explains extensive donor screening and virus testing/inactivation steps because it is derived from human source material. In contrast, some European product information describes urokinase that is extracted from human urine. These differences matter commercially: biologic sourcing and validation requirements make it harder for many manufacturers to enter, and they increase the importance of quality systems, change control, and reliable supply chains.
On the demand side, the most basic driver is that blood clots are common, and a subset of them are severe enough that rapid clot removal is lifesaving or limb-saving. The U.S. CDC says up to 900,000 people in the United States are affected by venous thromboembolism (VTE) each year, and VTE is linked to tens of thousands of deaths. Globally, cardiovascular diseases are still the leading cause of death, and they overlap with clot problems and high-risk hospital populations. These facts do not mean every clot patient needs urokinase. Most patients receive anticoagulants and supportive care, not thrombolytics. But they explain why hospitals continue to need a set of clot-management tools, including thrombolytic drugs, for the most urgent cases.
In 2025, global Urokinase Lyophilized Powder production reached approximately 2490 BIU, with an average global market price of around US$ 30 per MIU. The global single-line production capacity ranges from 100 to 150 BIU per year. The industry's gross profit margin is approximately 25%-35%.
One of the clearest growth “pockets” for urokinase is catheter and access-device management. Modern medicine uses a large volume of central venous catheters for chemotherapy, nutrition, antibiotics, and dialysis. These devices can become blocked by thrombus or fibrin sheaths. In Europe, regulatory summaries describe urokinase use for clots in catheters or cannulae, which is essentially “catheter clearance.” Clinical literature on thrombolytic therapy for catheter occlusion discusses multiple agents and reports that thrombolytics can restore patency in a meaningful share of blocked catheters, with performance differences by drug and dosing strategy; this is a major reason hospitals keep thrombolytic protocols for catheter salvage. When catheter salvage works, it avoids line replacement, reduces procedure risk, and helps preserve access sites—especially important for dialysis and oncology patients. This clinical logic is also why companies publicly frame catheter clearance as an attractive commercial segment when they talk about bringing urokinase products back to market.
A second demand segment is catheter-directed thrombolysis (CDT) for limb-threatening peripheral arterial occlusion or extensive venous thrombosis, where drug is infused locally through a catheter rather than given as a full systemic infusion. Product information for urokinase in Europe explicitly describes acute peripheral arterial occlusions and notes that catheter-directed local lysis is the preferred method of administration for that scenario. More recent reviews also describe CDT as an effective endovascular method for thrombotic peripheral artery occlusions, while emphasizing the need for careful monitoring because bleeding and other complications are real. This creates a steady, procedure-linked demand for urokinase (and competing thrombolytics) in hospitals that perform vascular interventions. The market driver here is not only disease incidence; it is the expansion of interventional capability, better imaging, and more hospitals building vascular teams that can do “minimally invasive” clot removal rather than open surgery in selected patients.
At the same time, a major market trend is that urokinase is not the only clot-buster, and in some very large indications it has been replaced by other approaches. In acute ischemic stroke, for example, many regions use alteplase or tenecteplase, and mechanical thrombectomy has grown for large-vessel occlusions. In myocardial infarction, primary PCI has replaced thrombolysis in many systems where rapid catheterization is available. These shifts matter because they move thrombolytic use toward more specialized niches. In catheter clearance specifically, alteplase has strong clinical adoption in many settings, and reviews discuss its clearance rates and how other agents compare. So, one trend in the urokinase market is “narrower but deeper”: fewer broad, mass-market indications, but ongoing need in hospital procedures and device-related clots where protocols and economics favor certain agents.
This report delivers a comprehensive overview of the global Urokinase Lyophilized Powder market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Urokinase Lyophilized Powder. The Urokinase Lyophilized Powder market size, estimates, and forecasts are provided in terms of sales volume (BIU) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Urokinase Lyophilized Powder market comprehensively. Regional market sizes by Type, by Application, by Clinical Use, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Urokinase Lyophilized Powder manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Urokinase Lyophilized Powder Market Report

Report Metric Details
Report Name Urokinase Lyophilized Powder Market
Accounted market size in 2025 US$ 74.70 million
Forecasted market size in 2032 US$ 112 million
CAGR 5.5%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Animal Urokinase Powder
  • Human Urokinase Powder
Segment by Clinical Use
  • Pulmonary Embolism Thrombolysis
  • Deep Vein Thrombosis
  • Peripheral Arterial Occlusion Thrombolysis
  • Catheter / Cannula Occlusion Clearance
  • Others
Segment by Administration Approach
  • Systemic Infusion
  • Catheter-directed Thrombolysis (CDT)
  • Intracatheter Dwell / Lock Technique
Segment by Purity
  • Standard Clinical Grade
  • High-purity / Low-impurity Grade
  • Low Endotoxin / Low Bioburden Specifications
by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems, LIVZON, Wuhan Humanwell Pharma, Tianjin Biochem Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Clinical Use, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Urokinase Lyophilized Powder manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Urokinase Lyophilized Powder sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Urokinase Lyophilized Powder Market growing?

Ans: The Urokinase Lyophilized Powder Market witnessing a CAGR of 5.5% during the forecast period 2026-2032.

What is the Urokinase Lyophilized Powder Market size in 2032?

Ans: The Urokinase Lyophilized Powder Market size in 2032 will be US$ 112 million.

Who are the main players in the Urokinase Lyophilized Powder Market report?

Ans: The main players in the Urokinase Lyophilized Powder Market are Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems, LIVZON, Wuhan Humanwell Pharma, Tianjin Biochem Pharma

What are the Application segmentation covered in the Urokinase Lyophilized Powder Market report?

Ans: The Applications covered in the Urokinase Lyophilized Powder Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Urokinase Lyophilized Powder Market report?

Ans: The Types covered in the Urokinase Lyophilized Powder Market report are Animal Urokinase Powder, Human Urokinase Powder

1 Urokinase Lyophilized Powder Market Overview
1.1 Product Definition
1.2 Urokinase Lyophilized Powder by Type
1.2.1 Global Urokinase Lyophilized Powder Market Value by Type: 2025 vs 2032
1.2.2 Animal Urokinase Powder
1.2.3 Human Urokinase Powder
1.3 Urokinase Lyophilized Powder by Clinical Use
1.3.1 Global Urokinase Lyophilized Powder Market Value by Clinical Use: 2025 vs 2032
1.3.2 Pulmonary Embolism Thrombolysis
1.3.3 Deep Vein Thrombosis
1.3.4 Peripheral Arterial Occlusion Thrombolysis
1.3.5 Catheter / Cannula Occlusion Clearance
1.3.6 Others
1.4 Urokinase Lyophilized Powder by Administration Approach
1.4.1 Global Urokinase Lyophilized Powder Market Value by Administration Approach: 2025 vs 2032
1.4.2 Systemic Infusion
1.4.3 Catheter-directed Thrombolysis (CDT)
1.4.4 Intracatheter Dwell / Lock Technique
1.5 Urokinase Lyophilized Powder by Purity
1.5.1 Global Urokinase Lyophilized Powder Market Value by Purity: 2025 vs 2032
1.5.2 Standard Clinical Grade
1.5.3 High-purity / Low-impurity Grade
1.5.4 Low Endotoxin / Low Bioburden Specifications
1.6 Urokinase Lyophilized Powder by Application
1.6.1 Global Urokinase Lyophilized Powder Market Value by Application: 2025 vs 2032
1.6.2 Hospital
1.6.3 Clinic
1.6.4 Others
1.7 Global Urokinase Lyophilized Powder Market Size Estimates and Forecasts
1.7.1 Global Urokinase Lyophilized Powder Revenue 2021–2032
1.7.2 Global Urokinase Lyophilized Powder Sales 2021–2032
1.7.3 Global Urokinase Lyophilized Powder Market Average Price (2021–2032)
1.8 Assumptions and Limitations
2 Urokinase Lyophilized Powder Market Competition by Manufacturers
2.1 Global Urokinase Lyophilized Powder Sales Market Share by Manufacturers (2021–2026)
2.2 Global Urokinase Lyophilized Powder Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Urokinase Lyophilized Powder Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Urokinase Lyophilized Powder, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Urokinase Lyophilized Powder, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Urokinase Lyophilized Powder, Product Types and Applications
2.7 Global Key Manufacturers of Urokinase Lyophilized Powder, Date of Entry into the Industry
2.8 Global Urokinase Lyophilized Powder Market Competitive Situation and Trends
2.8.1 Global Urokinase Lyophilized Powder Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Urokinase Lyophilized Powder Players Market Share by Revenue
2.8.3 Global Urokinase Lyophilized Powder Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Urokinase Lyophilized Powder Market Scenario by Region
3.1 Global Urokinase Lyophilized Powder Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Urokinase Lyophilized Powder Sales by Region: 2021–2032
3.2.1 Global Urokinase Lyophilized Powder Sales by Region: 2021–2026
3.2.2 Global Urokinase Lyophilized Powder Sales by Region: 2027–2032
3.3 Global Urokinase Lyophilized Powder Revenue by Region: 2021–2032
3.3.1 Global Urokinase Lyophilized Powder Revenue by Region: 2021–2026
3.3.2 Global Urokinase Lyophilized Powder Revenue by Region: 2027–2032
3.4 North America Urokinase Lyophilized Powder Market Facts & Figures by Country
3.4.1 North America Urokinase Lyophilized Powder Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Urokinase Lyophilized Powder Sales by Country (2021–2032)
3.4.3 North America Urokinase Lyophilized Powder Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Urokinase Lyophilized Powder Market Facts & Figures by Country
3.5.1 Europe Urokinase Lyophilized Powder Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Urokinase Lyophilized Powder Sales by Country (2021–2032)
3.5.3 Europe Urokinase Lyophilized Powder Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Urokinase Lyophilized Powder Market Facts & Figures by Region
3.6.1 Asia Pacific Urokinase Lyophilized Powder Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Urokinase Lyophilized Powder Sales by Region (2021–2032)
3.6.3 Asia Pacific Urokinase Lyophilized Powder Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Urokinase Lyophilized Powder Market Facts & Figures by Country
3.7.1 Latin America Urokinase Lyophilized Powder Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Urokinase Lyophilized Powder Sales by Country (2021–2032)
3.7.3 Latin America Urokinase Lyophilized Powder Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Urokinase Lyophilized Powder Market Facts & Figures by Country
3.8.1 Middle East and Africa Urokinase Lyophilized Powder Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Urokinase Lyophilized Powder Sales by Country (2021–2032)
3.8.3 Middle East and Africa Urokinase Lyophilized Powder Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Urokinase Lyophilized Powder Sales by Type (2021–2032)
4.1.1 Global Urokinase Lyophilized Powder Sales by Type (2021–2026)
4.1.2 Global Urokinase Lyophilized Powder Sales by Type (2027–2032)
4.1.3 Global Urokinase Lyophilized Powder Sales Market Share by Type (2021–2032)
4.2 Global Urokinase Lyophilized Powder Revenue by Type (2021–2032)
4.2.1 Global Urokinase Lyophilized Powder Revenue by Type (2021–2026)
4.2.2 Global Urokinase Lyophilized Powder Revenue by Type (2027–2032)
4.2.3 Global Urokinase Lyophilized Powder Revenue Market Share by Type (2021–2032)
4.3 Global Urokinase Lyophilized Powder Price by Type (2021–2032)
5 Segment by Application
5.1 Global Urokinase Lyophilized Powder Sales by Application (2021–2032)
5.1.1 Global Urokinase Lyophilized Powder Sales by Application (2021–2026)
5.1.2 Global Urokinase Lyophilized Powder Sales by Application (2027–2032)
5.1.3 Global Urokinase Lyophilized Powder Sales Market Share by Application (2021–2032)
5.2 Global Urokinase Lyophilized Powder Revenue by Application (2021–2032)
5.2.1 Global Urokinase Lyophilized Powder Revenue by Application (2021–2026)
5.2.2 Global Urokinase Lyophilized Powder Revenue by Application (2027–2032)
5.2.3 Global Urokinase Lyophilized Powder Revenue Market Share by Application (2021–2032)
5.3 Global Urokinase Lyophilized Powder Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Syner-Med
6.1.1 Syner-Med Company Information
6.1.2 Syner-Med Description and Business Overview
6.1.3 Syner-Med Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Syner-Med Urokinase Lyophilized Powder Product Portfolio
6.1.5 Syner-Med Recent Developments/Updates
6.2 Wanhua Biochem
6.2.1 Wanhua Biochem Company Information
6.2.2 Wanhua Biochem Description and Business Overview
6.2.3 Wanhua Biochem Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Wanhua Biochem Urokinase Lyophilized Powder Product Portfolio
6.2.5 Wanhua Biochem Recent Developments/Updates
6.3 Jiangxi Haoran Bio-Pharma
6.3.1 Jiangxi Haoran Bio-Pharma Company Information
6.3.2 Jiangxi Haoran Bio-Pharma Description and Business Overview
6.3.3 Jiangxi Haoran Bio-Pharma Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Jiangxi Haoran Bio-Pharma Urokinase Lyophilized Powder Product Portfolio
6.3.5 Jiangxi Haoran Bio-Pharma Recent Developments/Updates
6.4 Jiangsu Aidea Pharmaceutical
6.4.1 Jiangsu Aidea Pharmaceutical Company Information
6.4.2 Jiangsu Aidea Pharmaceutical Description and Business Overview
6.4.3 Jiangsu Aidea Pharmaceutical Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Jiangsu Aidea Pharmaceutical Urokinase Lyophilized Powder Product Portfolio
6.4.5 Jiangsu Aidea Pharmaceutical Recent Developments/Updates
6.5 Techpool
6.5.1 Techpool Company Information
6.5.2 Techpool Description and Business Overview
6.5.3 Techpool Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Techpool Urokinase Lyophilized Powder Product Portfolio
6.5.5 Techpool Recent Developments/Updates
6.6 Microbic Biosystems
6.6.1 Microbic Biosystems Company Information
6.6.2 Microbic Biosystems Description and Business Overview
6.6.3 Microbic Biosystems Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Microbic Biosystems Urokinase Lyophilized Powder Product Portfolio
6.6.5 Microbic Biosystems Recent Developments/Updates
6.7 LIVZON
6.7.1 LIVZON Company Information
6.7.2 LIVZON Description and Business Overview
6.7.3 LIVZON Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 LIVZON Urokinase Lyophilized Powder Product Portfolio
6.7.5 LIVZON Recent Developments/Updates
6.8 Wuhan Humanwell Pharma
6.8.1 Wuhan Humanwell Pharma Company Information
6.8.2 Wuhan Humanwell Pharma Description and Business Overview
6.8.3 Wuhan Humanwell Pharma Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Wuhan Humanwell Pharma Urokinase Lyophilized Powder Product Portfolio
6.8.5 Wuhan Humanwell Pharma Recent Developments/Updates
6.9 Tianjin Biochem Pharma
6.9.1 Tianjin Biochem Pharma Company Information
6.9.2 Tianjin Biochem Pharma Description and Business Overview
6.9.3 Tianjin Biochem Pharma Urokinase Lyophilized Powder Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Tianjin Biochem Pharma Urokinase Lyophilized Powder Product Portfolio
6.9.5 Tianjin Biochem Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Urokinase Lyophilized Powder Industry Chain Analysis
7.2 Urokinase Lyophilized Powder Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Urokinase Lyophilized Powder Production Mode & Process Analysis
7.4 Urokinase Lyophilized Powder Sales and Marketing
7.4.1 Urokinase Lyophilized Powder Sales Channels
7.4.2 Urokinase Lyophilized Powder Distributors
7.5 Urokinase Lyophilized Powder Customer Analysis
8 Urokinase Lyophilized Powder Market Dynamics
8.1 Urokinase Lyophilized Powder Industry Trends
8.2 Urokinase Lyophilized Powder Market Drivers
8.3 Urokinase Lyophilized Powder Market Challenges
8.4 Urokinase Lyophilized Powder Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
LIVZON
Syner-Med
Microbic Biosystems
Wuhan Humanwell Pharma
Tianjin Biochem Pharma
List of Tables
 Table 1. Global Urokinase Lyophilized Powder Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Urokinase Lyophilized Powder Market Value by Clinical Use (US$ Million), 2025 vs 2032
 Table 3. Global Urokinase Lyophilized Powder Market Value by Administration Approach (US$ Million), 2025 vs 2032
 Table 4. Global Urokinase Lyophilized Powder Market Value by Purity (US$ Million), 2025 vs 2032
 Table 5. Global Urokinase Lyophilized Powder Market Value by Application (US$ Million), 2025 vs 2032
 Table 6. Global Urokinase Lyophilized Powder Market Competitive Situation by Manufacturers in 2025
 Table 7. Global Urokinase Lyophilized Powder Sales (BIU) of Key Manufacturers (2021–2026)
 Table 8. Global Urokinase Lyophilized Powder Sales Market Share by Manufacturers (2021–2026)
 Table 9. Global Urokinase Lyophilized Powder Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 10. Global Urokinase Lyophilized Powder Revenue Share by Manufacturers (2021–2026)
 Table 11. Global Market Urokinase Lyophilized Powder Average Price (USD/MIU) of Key Manufacturers (2021–2026)
 Table 12. Global Key Players of Urokinase Lyophilized Powder, Industry Ranking, 2023 vs 2024 vs 2025
 Table 13. Global Key Manufacturers of Urokinase Lyophilized Powder, Manufacturing Sites and Headquarters
 Table 14. Global Key Manufacturers of Urokinase Lyophilized Powder, Product Types and Applications
 Table 15. Global Key Manufacturers of Urokinase Lyophilized Powder, Date of Entry into the Industry
 Table 16. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 17. Global Urokinase Lyophilized Powder Companies by Tier (Tier 1, Tier 2, Tier 3), based on Urokinase Lyophilized Powder Revenue, 2025
 Table 18. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 19. Global Urokinase Lyophilized Powder Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 20. Global Urokinase Lyophilized Powder Sales by Region (BIU), 2021–2026
 Table 21. Global Urokinase Lyophilized Powder Sales Market Share by Region (2021–2026)
 Table 22. Global Urokinase Lyophilized Powder Sales by Region (BIU), 2027–2032
 Table 23. Global Urokinase Lyophilized Powder Sales Market Share by Region (2027–2032)
 Table 24. Global Urokinase Lyophilized Powder Revenue by Region (US$ Million), 2021–2026
 Table 25. Global Urokinase Lyophilized Powder Revenue Market Share by Region (2021–2026)
 Table 26. Global Urokinase Lyophilized Powder Revenue by Region (US$ Million), 2027–2032
 Table 27. Global Urokinase Lyophilized Powder Revenue Market Share by Region (2027–2032)
 Table 28. North America Urokinase Lyophilized Powder Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 29. North America Urokinase Lyophilized Powder Sales by Country (BIU), 2021–2026
 Table 30. North America Urokinase Lyophilized Powder Sales by Country (BIU), 2027–2032
 Table 31. North America Urokinase Lyophilized Powder Revenue by Country (US$ Million), 2021–2026
 Table 32. North America Urokinase Lyophilized Powder Revenue by Country (US$ Million), 2027–2032
 Table 33. Europe Urokinase Lyophilized Powder Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 34. Europe Urokinase Lyophilized Powder Sales by Country (BIU), 2021–2026
 Table 35. Europe Urokinase Lyophilized Powder Sales by Country (BIU), 2027–2032
 Table 36. Europe Urokinase Lyophilized Powder Revenue by Country (US$ Million), 2021–2026
 Table 37. Europe Urokinase Lyophilized Powder Revenue by Country (US$ Million), 2027–2032
 Table 38. Asia Pacific Urokinase Lyophilized Powder Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 39. Asia Pacific Urokinase Lyophilized Powder Sales by Region (BIU), 2021–2026
 Table 40. Asia Pacific Urokinase Lyophilized Powder Sales by Region (BIU), 2027–2032
 Table 41. Asia Pacific Urokinase Lyophilized Powder Revenue by Region (US$ Million), 2021–2026
 Table 42. Asia Pacific Urokinase Lyophilized Powder Revenue by Region (US$ Million), 2027–2032
 Table 43. Latin America Urokinase Lyophilized Powder Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 44. Latin America Urokinase Lyophilized Powder Sales by Country (BIU), 2021–2026
 Table 45. Latin America Urokinase Lyophilized Powder Sales by Country (BIU), 2027–2032
 Table 46. Latin America Urokinase Lyophilized Powder Revenue by Country (US$ Million), 2021–2026
 Table 47. Latin America Urokinase Lyophilized Powder Revenue by Country (US$ Million), 2027–2032
 Table 48. Middle East and Africa Urokinase Lyophilized Powder Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 49. Middle East and Africa Urokinase Lyophilized Powder Sales by Country (BIU), 2021–2026
 Table 50. Middle East and Africa Urokinase Lyophilized Powder Sales by Country (BIU), 2027–2032
 Table 51. Middle East and Africa Urokinase Lyophilized Powder Revenue by Country (US$ Million), 2021–2026
 Table 52. Middle East and Africa Urokinase Lyophilized Powder Revenue by Country (US$ Million), 2027–2032
 Table 53. Global Urokinase Lyophilized Powder Sales (BIU) by Type (2021–2026)
 Table 54. Global Urokinase Lyophilized Powder Sales (BIU) by Type (2027–2032)
 Table 55. Global Urokinase Lyophilized Powder Sales Market Share by Type (2021–2026)
 Table 56. Global Urokinase Lyophilized Powder Sales Market Share by Type (2027–2032)
 Table 57. Global Urokinase Lyophilized Powder Revenue (US$ Million) by Type (2021–2026)
 Table 58. Global Urokinase Lyophilized Powder Revenue (US$ Million) by Type (2027–2032)
 Table 59. Global Urokinase Lyophilized Powder Revenue Market Share by Type (2021–2026)
 Table 60. Global Urokinase Lyophilized Powder Revenue Market Share by Type (2027–2032)
 Table 61. Global Urokinase Lyophilized Powder Price (USD/MIU) by Type (2021–2026)
 Table 62. Global Urokinase Lyophilized Powder Price (USD/MIU) by Type (2027–2032)
 Table 63. Global Urokinase Lyophilized Powder Sales (BIU) by Application (2021–2026)
 Table 64. Global Urokinase Lyophilized Powder Sales (BIU) by Application (2027–2032)
 Table 65. Global Urokinase Lyophilized Powder Sales Market Share by Application (2021–2026)
 Table 66. Global Urokinase Lyophilized Powder Sales Market Share by Application (2027–2032)
 Table 67. Global Urokinase Lyophilized Powder Revenue (US$ Million) by Application (2021–2026)
 Table 68. Global Urokinase Lyophilized Powder Revenue (US$ Million) by Application (2027–2032)
 Table 69. Global Urokinase Lyophilized Powder Revenue Market Share by Application (2021–2026)
 Table 70. Global Urokinase Lyophilized Powder Revenue Market Share by Application (2027–2032)
 Table 71. Global Urokinase Lyophilized Powder Price (USD/MIU) by Application (2021–2026)
 Table 72. Global Urokinase Lyophilized Powder Price (USD/MIU) by Application (2027–2032)
 Table 73. Syner-Med Company Information
 Table 74. Syner-Med Description and Business Overview
 Table 75. Syner-Med Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 76. Syner-Med Urokinase Lyophilized Powder Product
 Table 77. Syner-Med Recent Developments/Updates
 Table 78. Wanhua Biochem Company Information
 Table 79. Wanhua Biochem Description and Business Overview
 Table 80. Wanhua Biochem Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 81. Wanhua Biochem Urokinase Lyophilized Powder Product
 Table 82. Wanhua Biochem Recent Developments/Updates
 Table 83. Jiangxi Haoran Bio-Pharma Company Information
 Table 84. Jiangxi Haoran Bio-Pharma Description and Business Overview
 Table 85. Jiangxi Haoran Bio-Pharma Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 86. Jiangxi Haoran Bio-Pharma Urokinase Lyophilized Powder Product
 Table 87. Jiangxi Haoran Bio-Pharma Recent Developments/Updates
 Table 88. Jiangsu Aidea Pharmaceutical Company Information
 Table 89. Jiangsu Aidea Pharmaceutical Description and Business Overview
 Table 90. Jiangsu Aidea Pharmaceutical Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 91. Jiangsu Aidea Pharmaceutical Urokinase Lyophilized Powder Product
 Table 92. Jiangsu Aidea Pharmaceutical Recent Developments/Updates
 Table 93. Techpool Company Information
 Table 94. Techpool Description and Business Overview
 Table 95. Techpool Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 96. Techpool Urokinase Lyophilized Powder Product
 Table 97. Techpool Recent Developments/Updates
 Table 98. Microbic Biosystems Company Information
 Table 99. Microbic Biosystems Description and Business Overview
 Table 100. Microbic Biosystems Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 101. Microbic Biosystems Urokinase Lyophilized Powder Product
 Table 102. Microbic Biosystems Recent Developments/Updates
 Table 103. LIVZON Company Information
 Table 104. LIVZON Description and Business Overview
 Table 105. LIVZON Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 106. LIVZON Urokinase Lyophilized Powder Product
 Table 107. LIVZON Recent Developments/Updates
 Table 108. Wuhan Humanwell Pharma Company Information
 Table 109. Wuhan Humanwell Pharma Description and Business Overview
 Table 110. Wuhan Humanwell Pharma Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 111. Wuhan Humanwell Pharma Urokinase Lyophilized Powder Product
 Table 112. Wuhan Humanwell Pharma Recent Developments/Updates
 Table 113. Tianjin Biochem Pharma Company Information
 Table 114. Tianjin Biochem Pharma Description and Business Overview
 Table 115. Tianjin Biochem Pharma Urokinase Lyophilized Powder Sales (BIU), Revenue (US$ Million), Price (USD/MIU), and Gross Margin (2021–2026)
 Table 116. Tianjin Biochem Pharma Urokinase Lyophilized Powder Product
 Table 117. Tianjin Biochem Pharma Recent Developments/Updates
 Table 118. Key Raw Materials Lists
 Table 119. Raw Materials Key Suppliers Lists
 Table 120. Urokinase Lyophilized Powder Distributors List
 Table 121. Urokinase Lyophilized Powder Customers List
 Table 122. Urokinase Lyophilized Powder Market Trends
 Table 123. Urokinase Lyophilized Powder Market Drivers
 Table 124. Urokinase Lyophilized Powder Market Challenges
 Table 125. Urokinase Lyophilized Powder Market Restraints
 Table 126. Research Programs/Design for This Report
 Table 127. Key Data Information from Secondary Sources
 Table 128. Key Data Information from Primary Sources
 Table 129. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Urokinase Lyophilized Powder
 Figure 2. Global Urokinase Lyophilized Powder Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Urokinase Lyophilized Powder Market Share by Type: 2025 & 2032
 Figure 4. Animal Urokinase Powder Product Picture
 Figure 5. Human Urokinase Powder Product Picture
 Figure 6. Global Urokinase Lyophilized Powder Market Value by Clinical Use (US$ Million), 2021–2032
 Figure 7. Global Urokinase Lyophilized Powder Market Share by Clinical Use: 2025 vs 2032
 Figure 8. Pulmonary Embolism Thrombolysis Product Picture
 Figure 9. Deep Vein Thrombosis Product Picture
 Figure 10. Peripheral Arterial Occlusion Thrombolysis Product Picture
 Figure 11. Catheter / Cannula Occlusion Clearance Product Picture
 Figure 12. Others Product Picture
 Figure 13. Global Urokinase Lyophilized Powder Market Value by Administration Approach (US$ Million), 2021–2032
 Figure 14. Global Urokinase Lyophilized Powder Market Share by Administration Approach: 2025 vs 2032
 Figure 15. Systemic Infusion Product Picture
 Figure 16. Catheter-directed Thrombolysis (CDT) Product Picture
 Figure 17. Intracatheter Dwell / Lock Technique Product Picture
 Figure 18. Global Urokinase Lyophilized Powder Market Value by Purity (US$ Million), 2021–2032
 Figure 19. Global Urokinase Lyophilized Powder Market Share by Purity: 2025 vs 2032
 Figure 20. Standard Clinical Grade Product Picture
 Figure 21. High-purity / Low-impurity Grade Product Picture
 Figure 22. Low Endotoxin / Low Bioburden Specifications Product Picture
 Figure 23. Global Urokinase Lyophilized Powder Market Value by Application (US$ Million), 2021–2032
 Figure 24. Global Urokinase Lyophilized Powder Market Share by Application: 2025 & 2032
 Figure 25. Hospital
 Figure 26. Clinic
 Figure 27. Others
 Figure 28. Global Urokinase Lyophilized Powder Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 29. Global Urokinase Lyophilized Powder Market Size (US$ Million), 2021–2032
 Figure 30. Global Urokinase Lyophilized Powder Sales (BIU), 2021–2032
 Figure 31. Global Urokinase Lyophilized Powder Average Price (USD/MIU), 2021–2032
 Figure 32. Urokinase Lyophilized Powder Report Years Considered
 Figure 33. Urokinase Lyophilized Powder Sales Share by Manufacturers in 2025
 Figure 34. Global Urokinase Lyophilized Powder Revenue Share by Manufacturers in 2025
 Figure 35. Top 5 and Top 10 Global Urokinase Lyophilized Powder Players: Market Share by Revenue in Urokinase Lyophilized Powder in 2025
 Figure 36. Urokinase Lyophilized Powder Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 37. Global Urokinase Lyophilized Powder Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 38. North America Urokinase Lyophilized Powder Sales Market Share by Country (2021–2032)
 Figure 39. North America Urokinase Lyophilized Powder Revenue Market Share by Country (2021–2032)
 Figure 40. United States Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Canada Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Europe Urokinase Lyophilized Powder Sales Market Share by Country (2021–2032)
 Figure 43. Europe Urokinase Lyophilized Powder Revenue Market Share by Country (2021–2032)
 Figure 44. Germany Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. France Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. U.K. Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Italy Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Russia Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Asia Pacific Urokinase Lyophilized Powder Sales Market Share by Region (2021–2032)
 Figure 50. Asia Pacific Urokinase Lyophilized Powder Revenue Market Share by Region (2021–2032)
 Figure 51. China Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Japan Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. South Korea Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. India Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Australia Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. China Taiwan Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 57. Indonesia Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 58. Thailand Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 59. Malaysia Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 60. Latin America Urokinase Lyophilized Powder Sales Market Share by Country (2021–2032)
 Figure 61. Latin America Urokinase Lyophilized Powder Revenue Market Share by Country (2021–2032)
 Figure 62. Mexico Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 63. Brazil Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 64. Argentina Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 65. Middle East and Africa Urokinase Lyophilized Powder Sales Market Share by Country (2021–2032)
 Figure 66. Middle East and Africa Urokinase Lyophilized Powder Revenue Market Share by Country (2021–2032)
 Figure 67. Turkey Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 68. Saudi Arabia Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 69. UAE Urokinase Lyophilized Powder Revenue Growth Rate (US$ Million), 2021–2032
 Figure 70. Global Sales Market Share of Urokinase Lyophilized Powder by Type (2021–2032)
 Figure 71. Global Revenue Market Share of Urokinase Lyophilized Powder by Type (2021–2032)
 Figure 72. Global Urokinase Lyophilized Powder Price (USD/MIU) by Type (2021–2032)
 Figure 73. Global Sales Market Share of Urokinase Lyophilized Powder by Application (2021–2032)
 Figure 74. Global Revenue Market Share of Urokinase Lyophilized Powder by Application (2021–2032)
 Figure 75. Global Urokinase Lyophilized Powder Price (USD/MIU) by Application (2021–2032)
 Figure 76. Urokinase Lyophilized Powder Value Chain
 Figure 77. Channels of Distribution (Direct Vs Distribution)
 Figure 78. Bottom-up and Top-down Approaches for This Report
 Figure 79. Data Triangulation
 Figure 80. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Urokinase Market Research Report 2025
Global Urokinase Injection Market Research Report 2024
Global Urokinase for Injection Market Insights Forecast to 2030
Global Urokinase Powder Market Research Report 2024
Global uPA ELISA Kits Market Research Report 2024
Global Specific Plasminogen Activator Market Research Report 2024
Global Enterokinase Market Research Report 2025
Tissue Plasminogen Activator Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Non specific Plasminogen Activator Market Research Report 2024
Global Urease Powder Market Research Report 2024
Global Prevention and Diagnosis of Chicken Mycoplasma Disease Market Research Report 2024
Human Alpha1 Proteinase Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Trypsin Lyophilized Powder Market Research Report 2024
Global Medical Thrombolytic Enzyme Market Research Report 2024
Global Plasminogen Market Insights Forecast to 2030
Global Human Trypsin Market Research Report 2024
Global Recombinant Uricase Market Research Report 2024
Global Thrombolytic Drug Market Insights Forecast to 2030
Global Pepsin Market Insights Forecast to 2030
Global Medical Plasmin Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions